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Abstract
Background: Prader-Willi syndrome (PWS) is a rare multisystem genetic disease leading to
severe complications mainly related to obesity. We strongly lack information on the natural history
of this complex disease and on what factors are involved in its evolution and its outcome. One of
the objectives of the French reference centre for Prader-Willi syndrome set-up in 2004 was to set-
up a database in order to make the inventory of Prader-Willi syndrome cases and initiate a national
cohort study in the area covered by the centre.
Description: the database includes medical data of children and adolescents with Prader-Willi
syndrome, details about their management, socio-demographic data on their families, psychological
data and quality of life of the parents. The tools and organisation used to ensure data collection and
data quality in respect of good clinical practice procedures are discussed, and main characteristics
of our Prader-Willi population at inclusion are presented.
Conclusion: this database covering all the aspects of PWS clinical, psychological and social profiles,
including familial psychological and quality of life will be a powerful tool for retrospective studies
concerning this complex and multi factorial disease and could be a basis for the design of future
prospective multicentric studies. The complete database and the Stata.do files are available to any
researcher wishing to use them for non-commercial purposes and can be provided upon request
to the corresponding author.
Background
Prader-Willi syndrome (PWS) is a rare genetic neurodevel-
opmental disorder related to the lack of expression of
paternal genes in the q11-q13 region of chromosome 15
first described in 1956 [1]. The incidence of PWS is about
one out of 25000 births [2-4], most cases are sporadic and
familial cases are rare. PWS infants exhibit severe hypoto-
nia already present at birth that partially improves,
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explaining in part suckling and swallowing troubles, fail-
ure to thrive (i.e. failure to get weight besides normal or
increased caloric intake) as well as delayed psycho-motor
development [5-7]. After this initial phase of about 2
years, the most striking sign appears: an early and severe
obesity related to an increasing appetite and the decrease
of satiety with an overwhelming eating obsession [8]. Fur-
thermore, a wide range of associated troubles is reported
in children, adolescents and adults: low and delayed
motor and oral-motor skills, learning disabilities, growth
hormone and sex hormones deficiencies probably due to
an unknown hypothalamic dysfunction and resulting in
short stature, increased body fat with a decreased lean
mass, cryptorchidism and absence or blunted puberty [8].
Other common concerns include strabismus, scoliosis,
osteoporosis, type 2 diabetes mellitus, hypertension,
hypoventilation, heart failure, skin problems, sleep dis-
turbances and skin picking (sometimes severe). Early
diagnosis confirmed by genetic analysis combined with
multidisciplinary care including hormonal therapies can
dramatically smooth over PWS troubles and improve the
quality of life of these patients and their family [9-13].
However, the constant and long-term need for food
restriction, behaviour management and medical care may
be stressful for PWS patients and family members [14,15].
In 2003, the French Ministry of Health launched a strate-
gic plan to optimize the diagnosis and the care of people
with rare disorders and strongly encouraged the setting-up
of reference centres for rare diseases. Since the late 90's,
French teams involved in PWS care had initiated collabo-
rations to share clinical knowledge and experience and in
2004, the French Ministry of Health agreed to approve a
reference centre for Prader-Willi syndrome, covering the
southern half of the country. In 2007 the reference centre
was asked to extend to the whole country with the help of
the French family association. PWS reference centre, as
other reference centres, has three main goals: optimize
patient's diagnosis, care and management throughout life,
inform and train health professionals and develop and/or
support clinical, epidemiological and basic research
projects. The aim of this article is to describe the database
constructed to reach one of the first objectives of PWS ref-
erence centre: to take inventory of PWS cases and initiate
a cohort study in the area covered by the centre. This data-
base will be of primary interest to improve the knowledge
of PWS disease: it will be a powerful tool for future spe-
cific research projects such as epidemiological studies. We
strongly lack information on the natural history of this
severe disease, on factors involved in its evolution and on
the outcomes of these children. There are few cohort stud-
ies [16-19] and few data related to overall PWS patients
and family's cares are available. To our knowledge, there
is no published database covering all the aspects of PWS
clinical, psychological and social profiles, including
familial psychological, quality of life and type of care.
Data collected could be added to the European database
in development [20] as our team participated to the
French group of the European database.
Construction and content
Our objective was to describe in a cross sectional
approach clinical and psychological characteristics of chil-
dren and adolescents with PWS, their management and
follow-up as well as their parents' psychological profile
and quality of life. Searches of PWS physicians' medical
records, PWS patients association listing and genetic diag-
nosis laboratory databases allowed us to estimate the total
eligible PWS patients, about 180 in the reference centre
area in 2004. Based on the estimated prevalence of the dis-
ease ranging from 1/25 000 to 1/30 000 and a total pop-
ulation of 260 000 births per year in the area, the
theoretical calculated number fell between 164 and 198
children and adolescents. All of the paediatric endocrinol-
ogists (public and private) taking care of PWS patients,
epidemiologists and psychologists of the reference centre
have been involved in study design, forms building and
validation processes to ensure data collection feasibility
and data quality. This first step was of primary interest
because the huge amount of data that could be gathered
from these PWS patients presenting severe multiple
pathologies had to be sorted out and simplified in order
to obtain standardized questionnaires covering most of
the components of this complex disease and adapted to
physicians' work environment and habits. Question-
naires' design has been discussed during five meetings and
was completed in 1 year. Consensus has been reach on i)
a baseline form including Medical and Socio-Demo-
graphic data (MSD form) filled in by patient's physician
and a familial psychological and quality of life form filled
in by the parents ii) a yearly follow-up form including
medical and psychological data of the patients iii) this
questionnaire will be subsequently modified and adapted
to adult patients.
Medical and socio-demographic data at inclusion
MSD form is a 265-item paper questionnaire designed to
be filled in by each PWS patient's physician, according to
clinical examination and medical records information.
When completed, MSD form is mailed to the coordina-
tion team and data are entered into the database by a Clin-
ical Research Associate (CRA). Variables of the MSD form
are summarized in Table 1.
Mean time length required to complete this first MSD
form has been estimated to be 60 min (30 min during
medical consultation and 30 min dedicated to source data
collection). As in some cases PWS medical records may
require a long time to be inspected, five of the nine centresBMC Medical Genetics 2008, 9:89 http://www.biomedcentral.com/1471-2350/9/89
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required CRA assistance to fill in clinical data question-
naires.
Familial psychological data at inclusion
Familial psychological data were gathered using 3 differ-
ent paper forms, given and explained at a routine visit,
and filled in by the parents at home. In total, time length
required is about 45 to 60 min.
The first form corresponds to the Child Behaviour Check-
List questionnaire (CBCL), a well validated instrument
designed to assess parent-reported behavioural and emo-
tional problems [21-24]. It is appropriate for use in 1.5 to
18 years old- children and adolescent populations and
has been widely used in Prader Willi studies [25-28]. We
asked both parents to fill the CBCL together unless it was
impossible for familial reasons. CBCL questionnaires
have been computed using "Assessment Data Manager,
version 4.0" software to compute raw scores, T-scores and
clinical translated scores (clinical-borderline-normal)
[21,22].
The second form contains three validated scales evaluat-
ing parent-reported stress, anxiety and depression. Each
parent has to complete his/her own questionnaire sepa-
rately.
- the 14-item Perceived Stress Scale (PSS14) [29] is vali-
dated to measure last month's sensed stress. It is scaled in
a positive direction with a higher score denoting higher
stress. PSS-14 has been widely used in psychological stud-
ies due to its psychometrical properties [30].
- Spielberger Test Anxiety Inventory (STAI) (Y form, 20
items) [31] measures trait-anxiety (trait-anxiety is a per-
sonality feature, a usual and stable anxiety trend). It is
scaled in a positive direction and raw scores are trans-
formed in T-scores according to French norms [32]. STAI
is widely used in psychological studies and has good psy-
chometrical properties.
- Beck Depression Inventory-II (BDI-II) is a 13-item scale
[33] which allows depression severity measurement as
well as nervous depression versus anxiety differentiation.
The BDI-II is one of the most widely accepted clinical
instruments [30,34]. Higher scores indicate greater
depressive symptomatology. Participants with scores in
the moderate-to-severe range, suggesting clinically signifi-
Table 1: List of variables of the medical and socio-demographic (MSD) form
Domain Number of variables recorded
Identification of the patient 11
Genetic diagnosis 4
Comprehensive care 2
Medical history of the family 16
Parents data 8
Familial situation 6
Professional situation of the parents 10
Social status 3
Adhesion to the parents' association 3
Pregnancy 10
Birth 13
Auxological measurements 19
Endocrine dysfunctions:
- GH deficiency 12
- GH treatment 12
- Hypogonadism 7
- Cryptorchidism 4
- Hypothyroidism 6
Psychomotor development and language 20
Management:
- Nutritional management 4
- Physiotherapy 4
- Speech and language management 4
- Psychomotricity 4
- Ophthalmologic disorders 3
- ENT 4
- Other specific management 4
Behavioural troubles 32
Medical Complications 27BMC Medical Genetics 2008, 9:89 http://www.biomedcentral.com/1471-2350/9/89
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cant levels of depressive symptoms, were identified by the
psychologist of the reference centre; patient's physician
was informed and offered assistance to obtain further
assessment and treatment. This procedure is outlined to
families at the time the familial psychological question-
naires are given to them by the physician.
The third form is the 1997 World Health Organisation
Quality of Life Questionnaire (WHOQOL-BREF). This 26-
item questionnaire is a sound, cross-culturally valid
assessment of quality of life (QOL), as reflected by the
four domains explored (physical health, psychological
health, social relationships and environment) and its two
individually scored items about an individual's overall
perception of QOL and health. The four domains and the
two individual items are scaled in a positive direction with
higher scores denoting higher QOL. WHOQOL-BREF
must be filled in by each parent. This questionnaire has
been widely and internationally used, translated into
French and validated, and reported to be sensitive, accu-
rate and homogeneous [35].
The coordination centre in Toulouse conducted a pilot
study involving 12 Prader-Willi's families in order to con-
firm the feasibility of a familial psychological study. Fam-
ilies first received an explanation from the psychologist,
filled in the questionnaires at home and mailed them to
the coordination team of the reference centre (prepaid
envelops). In total, 18 out of 24 questionnaires (75%)
were returned in 4 weeks. None of the parents reported
difficulties about understanding and/or answering the
whole questionnaire, nor psychological difficulties
related to BDI-II questionnaire. We did not perform a sta-
tistical analysis on these questionnaires.
Follow-up form
A yearly follow-up paper form has to be completed to sup-
ply the longitudinal part of the study. It is filled in by
investigators according to patient's clinical examination
and medical records information. When completed, the
follow-up form is mailed to the coordination team and
data are entered into the database by a CRA. Variables of
the MSD follow-up form are summarized in Table 2.
Mean time length required to complete the follow-up
form has been estimated to 30 min (15 min during med-
ical consultation and 15 min dedicated to source data col-
lection).
The follow-up form includes a psychological question-
naire evaluating the overall psychopathology of patients
and filled in by the parents. This questionnaire has not
been validated yet but is routinely used for adults with
PWS by the coordination centre, which has been involved
in the care of adult PWS patients for many years [36]. We
chose this specific questionnaire in order to evaluate the
evolution of psychological troubles from childhood to
adulthood. Mean time to complete this questionnaire is
about 10 minutes.
Construction
Data entry is done using Microsoft® Access 2003 (Micro-
soft Corp, Redmond, WA 98052-6399, USA). Database
structure is as follows: Main table contains administrative
data plus MSD form items. For each of the three psycho-
logical and QOL questionnaires, scores are stored in a
table linked one-to-many to the main table. One table
linked one-to-many to the main table contains annual fol-
low-up items. A user friendly interface including rolling
menus and data entry forms has been built to allow data-
base use by unskilled users. In data entry forms, fields are
Table 2: List of variables of the follow-up medical and socio-demographic form (follow-up MSD form)
Variables of the follow-up medical and socio-demographic form (follow-up MSD form)
Patient identification
- Identification number, date, date of initial visit
- Changes in familial medical history and familial situation since previous visit
Auxological and clinical measurements
Height, weight, BMI, head circumference, waist, hip, pubertal stage, pulse, blood pressure, right- or left-handed
Medical complications, operations since previous visit
Psychomotor development
schoolar, extra-schoolar activities
Treatments
GH, treatment for hypogonadism, hypothyroidism, other
Management
Nutritional management, physiotherapy, speech and language management, psychomotricity, ophthalmology, orthopaedic, psychological 
management, psychiatric management, other specific management
Behavioural troubles
IQ, Food-related troubles, anxiety, depression, obsessive compulsive disorder, psychotic aspects
Biological data
Imaging dataBMC Medical Genetics 2008, 9:89 http://www.biomedcentral.com/1471-2350/9/89
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organized in regard to paper forms presentation and
include limits which where applicable to minimize the
risk of error during the data entry process.
A set of Stata 8.2 programs (StataCorp, College Station,
Texas 77845, USA) has been developed to quicken and
secure data management procedures prior to statistical
analyses. Briefly, all raw tables are match-merged, varia-
bles are labelled, recoded when needed and calculated
variables are computed to generate a Stata file containing
the whole study data. This procedure is completed with a
set of calculated coherence controls. Birth weight and
birth length are expressed in Standard Deviation (SD)
according to Usher and Mc Lean tables [37], BMI Z-scores
are calculated and obesity defined as BMI > 97th centile,
according to French reference curves for BMI [38].
Computing time required for this complete procedure is
about five minutes and the entire procedure can be done
by unskilled users, simply clicking on Stata.do files icons.
All calculations are recorded in a log file to ensure compu-
tation traceability, and log files are archived with main
data and results files every time a statistical analysis is per-
formed.
Data collection
Database and data collection have been approved by the
2 French national data protection authorities, the "Comité
Consultatif sur le Traitement de l'Information en matière
de Recherche dans le domaine de la Santé" (Advisory
council for treatment of information in terms of health-
care research) and the "Commission Nationale de l'Infor-
matique et des Libertés" (French Data Protection
Authority). We got the approval of the president of the
local ethic committee (CPP 1 Toulouse, Dr H. Grand-
jean). Data collection is monitored by CRA in respect of
Good Clinical Practice (ICH-GCP) procedures. All
patients with Prader-Willi syndrome aged 0 to 20 living in
the region covered by the reference centre are eligible to
participate. Exclusion criterion is lack of confirmation of
PWS by genetic diagnosis. The study is presented to all eli-
gible patients by their physician during a medical consul-
tation. After the informed written consent is obtained
from the patient and his family, investigators fill in clini-
cal forms and give psychological and QOL questionnaires
to the parents to be completed at home. Parents are asked
to fill PWS psychopathology questionnaire together on
behalf of the Prader-Willi child and each parent is asked
to fill its own psychological and QOL questionnaire. All
paper forms are returned to the reference centre coordina-
tion team and entered into the database by CRA as previ-
ously described. Data entry of all study forms at inclusion
(MSD, psychological and QOL) is done within one hour
and a half, including intermediary CBCL scores calcula-
tion using Assessment Data Manager software. Data entry
of follow-up forms is done within half an hour.
We introduced a double check procedure in order to
obtain high-quality data. i) patient's data are checked by
CRA at the time of data entry, using data management
forms to display summary or detailed data entered in the
database. These forms are written-protected to avoid
unwanted data modification and can be sorted and fil-
tered in various ways. ii) a set of calculated coherence con-
trols is computed monthly by CRA using Stata 8.2
software as previously described.
Error correction procedure is as follows: a standardized
request form is sent to the investigator to be filled in and
returned to the coordination team. When the investigator
answer is received, database values are corrected if needed,
date of corrections and name of CRA being noted on
request form. Request form is then archived with source
data.
Data entry quality has been assessed prior to the statistical
analysis of the transversal study (work in progress). We
randomly selected 10% of patient's medical records and
we compared source data with database data. Low error
rate (0.3%) confirmed the quality of the tools and proce-
dures used in this project. Further regular data quality con-
trols are scheduled, a double data entry procedure being
required if 5% error rate is exceeded.
Utility
This database will be a powerful tool to collect data on
patients presenting this complex and multi system disease
and will be a basis for the design of future prospective
multicentric studies. It might allow us to analyse the
strengths and weaknesses of follow-up strategies used in
everyday clinical practice, taking in account clinical
improvements as well as patient's psychological status
and parents psychological and quality of life repercus-
sions.
Moreover this database could help sharing experience
with other worldwide teams involved in management and
care of PWS patients; particularly those who also set-up
databases and could provide data to support the onset of
a future European PWS database.
This publication could also provide landmarks for other
teams having such a project and might be of help for
teams interested in setting up cohort studies in other rare
diseases involving some of the PWS related troubles.
Discussion
Nowadays, PWS research is clearly active as shown by the
outcome of expert's meetings (the 1st one held in ZurichBMC Medical Genetics 2008, 9:89 http://www.biomedcentral.com/1471-2350/9/89
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in 2002 and the 2nd in Toulouse in 2006). The genetic
research showed evidence about some phenotype-geno-
type correlations [39-42] and many clinical studies
mainly based on the effects of growth hormone (GH)
treatment have been published in children [43-46] and
adults with PWS [47-49]. In addition, post-marketing
databases [50,51] reported strong evidence for hormonal
therapy benefit and behaviour management efficiency.
Most of the data and particularly history and care came
from clinical studies involving a small number of patients
enrolled by few highly specialized teams, leading not only
to limit statistical power but also to emphasize bias
related to inclusion criterion, patients' selection and
team's routine clinical practice. Moreover these studies
being focused on a set of clinical and/or biological varia-
bles are unable to reflect the whole patients' profile. But,
on another hand, setting up a prospective study exploring
interactions between clinical treatment, psychological sta-
tus and familial context does not seem to be feasible,
mainly due to the high number of patients needed to be
included which is not compatible with a rare disease. At
last, most of clinical studies are of relatively short duration
and cannot reflect the long term evolution of the disease
nor period-specific difficulties related to clinical manage-
ment such as childhood to adult transition.
This database will be of primary interest to improve the
knowledge of PWS disease: it will be a powerful tool for
future specific research projects such as epidemiological
studies. Main characteristics of the population at inclu-
sion are listed in table 3. Today, two years after the begin-
ning of the inclusions, 146 patients (81% of estimated
PWS cases) have been included and none of the PWS fam-
ilies refused to be enrolled in the study. Therefore, we con-
sider that making the actual database to become an
exhaustive register including all eligible patients at a
national level is a realistic and feasible goal that will be
one of the reference centre objectives in the years to come.
The follow-up of such an exhaustive cohort could allow us
to improve the knowledge of the evolution of this disease,
to optimize therapies and to adjust multidisciplinary care
organisation, taking into account not only the PWS
patients' clinical profile but also their familial environ-
ment.
In that way, we noticed that data collection has been con-
sidered of great help by PWS physicians for everyday clin-
ical practice: transversal study questionnaires have been
reported to be a helpful tool to summarize PWS medical
history and yearly follow-up forms will provide an over-
view of the disease evolution that will help physicians to
underline the most topical issues of patient follow-up and
care. In that way, it can be considered as a clinical tool to
be used in complement of patient's medical records.
Table 3: Characteristics of the population at inclusion
Variables Number of observations Results expressed as % or median (min-max)
Sex ratio 146 52.7% boys
Chronological age 146 7.24 years (0.21–18.75)
Genetic diagnosis 146 Deletion 63.7%
Disomy 24%
Translocation 1.4%
Imprinting defect 2.0%
AMP* 8.9%
Age at genetic diagnosis 143 2 months (5 days-12 years)
Obesity 138 43.5%
GH treatment 139 85.6%
Maternal age at birth of PWS child 137 32 years (18–46)
Paternal age at birth of PWS child 137 34 years(22–62)
Married 137 89.8%
Number of siblings (including PWS child) 144 2 (1–9)
Profession of the father 125 Full time 87.2%
Part time 4.8%
No 8%
Profession of the mother 130 Full time 26.1%
Part time 28.5%
No 45.4%
Social economic status 124 Low 31.4%
Medium 46.8%
High 21.8%
Membership of French PW Association 129 59%
* AMP = Abnormal Methylation ProfileBMC Medical Genetics 2008, 9:89 http://www.biomedcentral.com/1471-2350/9/89
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We chose to start with paper forms centralized by a coor-
dination centre then entered into the database by CRA
rather than internet forms filled in by physicians. This
organization appears to be adapted to a rare disease study.
We also noted that giving life to the investigators' team
through meetings, e-mail newsletters, phone calls and
some further CRA travels to give help, maintained the
motivation and ensured the long-term involvement of all
members.
A further database development focused on adult PWS is
planed for the next year in a national basis and links
between the 2 databases will be developed and will allow
us to describe the long term follow-up of early diagnosed
patients receiving multidisciplinary care. This two-step
development has been decided because relevant data to
be gathered are clearly different between adults (i.e. aged
more than 20) and younger PWS patients. This difference
is due on one hand to the natural evolution of the disease
and on the other hand to the history of PWS diagnosis and
treatment: PWS genetic diagnosis became available in
routine in the early 90's [52] and has been followed by
major improvements in therapies, medical care and fol-
low-up organization. Therefore, for PWS patients aged
less than twenty, PWS genetic diagnosis was available in
the first years of life, hormonal therapies were widely used
in respect of guidelines and multi-disciplinary care of the
disease became widespread. In contrast, for PWS patients
aged more than twenty, PWS diagnosis has been based on
clinical signs then confirmed or sometimes undermined
by genetic diagnosis many years later. Hormonal therapy
was not routinely prescribed and psychological and social
cares were not developed enough. Therefore studying the
adult PWS population requires a specific tool, adapted to
the heterogeneity of the population and to the widespread
differences related to psychosocial status. Improving our
knowledge of the nowadays adult PWS patients' profile
will help to refine specific follow-up as well as to adapt
childhood to adult transition strategies.
Conclusion
In 2007 the French ministry of health has extended the
PWS reference centre area to the whole French territory,
prompting us to implement the database with the patients
of our whole country. This can be done without software
modifications, allowing us to focus on the training of
newly involved medical teams and on the study manage-
ment organisation. Adult database is also in progress and
a second CRA has been recruited to ensure the success of
this cohort study extension.
Availability and requirements
Complete listings of variables of the MSD and follow-up
forms are available at http://www.chu-toulouse.fr/
spip.php?rubrique892. The complete database and the
Stata.do files are available to any researcher wishing to use
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